This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.

NCBR – European Funds

Hemolens Diagnostics Spółka z o.o. (formerly LifeFlow Sp. z o.o.)
is implementing a project co-financed from the European Funds titled
“HEMOFLOW cloud-based platform for non-invasive hemodynamic diagnostics.”

Project objectives:
The project aims at developing a cloud-based technology platform HEMOFLOW for non-invasive diagnostics of coronary artery disease that combines anatomical and functional evaluation of coronary blood flow correlated with myocardial perfusion assessment.

Anticipated results:

The HEMOFLOW PLATFORM will become a unique tool for CAD diagnostics, delivering solutions based on computer modelling and computational fluid mechanics to allow physicians to generate an independent structural and functional evaluation with the use of a virtual 3D coronary artery model (virtual measurement of fractional flow reserve, FFR) coupled with a 3D visualization of the myocardium (virtual 3D perfusion maps).

Project value: PLN 19,417,540.50
Co-funding from European Funds: PLN 12,953,985.55


Between November 1, 2016 and December 31, 2018, Hemolens Diagnostics Spółka z o.o. (formerly LifeFlow Sp. z o.o.) carried out a project co-financed from European Funds.

The R&D project titled ”LifeFlow” was implemented under Support (Grant) Agreement No. 2018/LSI/03/03 made on March 29, 2018 as part of Grant Project No. POIR.01.03.01-00-0032/16 carried out by Life Science Innovations Sp. z o. o. SK.

Project objectives:

The aim of the project was product/technology development, including developing proprietary FFR-CT technology with parameters guaranteeing a continuous competitive advantage, obtaining certification and marketing authorization on selected markets, as well as the implementation of an intellectual property protection and management strategy.

Project value: PLN 3,000,000.00
Co-funding from European Funds: PLN 2,400,000.00

This is a medical device. Use it in accordance with the instructions.

Intended Use:

Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.